Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral FAB122 (edaravone) versus placebo in amyotrophic lateral sclerosis
NL-OMON54862Phase 3Withdrawn
- Sponsor
- Ferrer
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of edaravone, sponsored by Ferrer. Planned start Jun 2021; status: withdrawn.
02
Drugs
edaravone
Beyond the preview
Go deeper on NL-OMON54862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54862.